FDA approves atezolizumab after surgery for stage III dMMR colon cancer

The U.S. Food and Drug Administration on October 8 approved atezolizumab with chemotherapy after surgery for stage III colon cancer with deficient DNA mismatch repair, or dMMR. The decision expands treatment options aimed at preventing recurrence in this defined patient group, an outcome relevant to longer-term health after cancer.

The approval covers Tecentriq with a fluoropyrimidine and oxaliplatin in adults and children aged two years and older. A separate approval covers Tecentriq Hybreza, which combines atezolizumab with hyaluronidase, for patients aged 12 years and older who weigh at least 40 kilograms.

### Why the tumor’s biology matters

Mismatch repair is a cellular system for correcting DNA errors. Tumors with defective repair can accumulate many mutations, a feature the National Cancer Institute identifies as relevant to immunotherapy research in colorectal cancer. This biology helps explain why treatment studies distinguish these tumors from cancers with functioning mismatch repair.

The new indication is specific to stage III dMMR colon cancer. It should not be generalized to every colorectal tumor or every stage of disease. The practical significance is a more precisely defined postoperative option: both the cancer’s stage and its molecular characteristics determine whether this particular approval applies.

### What the trial found

The supporting ATOMIC study was a multicenter, randomized, open-label phase 3 trial involving 712 patients after complete surgical resection. Participants received either atezolizumab plus modified FOLFOX6 chemotherapy or chemotherapy alone. The median age was 64 years.

The trial’s main endpoint was disease-free survival. At a median follow-up of 40.9 months, estimated three-year disease-free survival was 86.3% with the combination and 76.2% with chemotherapy alone. The hazard ratio for recurrence or death was 0.50, with a 95% confidence interval of 0.35 to 0.73.

The difference between those three-year estimates was 10.1 percentage points. That absolute comparison helps put the relative result in perspective: a halving of the hazard does not mean that half of all treated patients avoided a recurrence because of immunotherapy.

These findings were published online in The New England Journal of Medicine on March 25, 2026. This week’s development is the regulatory decision, rather than the first publication of the trial results.

### Benefits come with additional toxicity

Grade 3 or 4 adverse events occurred in 84.1% of patients receiving the combination, compared with 71.9% receiving chemotherapy alone. The FDA also highlights warnings for immune-mediated adverse reactions and infusion reactions.

That safety burden matters in the postoperative setting, where treatment is intended to reduce future risk after the visible tumor has been removed. Evaluating the option requires attention to both the chance of remaining disease-free and the harms associated with additional treatment.

### What remains unresolved

Disease-free survival measures a different outcome from overall survival. The recurrence-or-death result should not be restated as a demonstrated halving of mortality, nor does this approval establish an effect on biological aging or general lifespan.

The study was open-label, and the FDA describes disease-free survival as investigator-assessed. Pediatric representation was particularly limited: the agency reports 711 adults and one pediatric participant. Broad age eligibility in the approval therefore should not be mistaken for extensive direct trial evidence across childhood.

For healthspan reporting, the relevant advance is an approved strategy to reduce recurrence risk in a specific cancer population. Its value must remain anchored to that population, the measured endpoint and the accompanying toxicity.